Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company, will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's 85th Scientific Sessions. The presentation, scheduled for June 22, 2025, will showcase results from a study titled 'Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice.' The poster session will take place at the ADA conference in Chicago from June 20-23, 2025, with the specific presentation scheduled for 12:30-1:30 PM in Hall F1. The data will be made available on Fractyl's website after the conference presentation.
Fractyl Health (NASDAQ: GUTS), un'azienda specializzata in terapie metaboliche, presenterà nuovi dati preclinici relativi alla sua piattaforma di terapia genica pancreatica Rejuva Smart GLP-1 durante la 85ª Sessione Scientifica dell'American Diabetes Association. La presentazione, prevista per il 22 giugno 2025, mostrerà i risultati di uno studio intitolato "Terapia genica pancreatica basata su GLP-1 a singola dose previene obesità e diabete in topi alimentati con dieta ricca di grassi." La sessione poster si terrà alla conferenza ADA di Chicago dal 20 al 23 giugno 2025, con la presentazione specifica programmata dalle 12:30 alle 13:30 nella Sala F1. I dati saranno disponibili sul sito web di Fractyl dopo la presentazione alla conferenza.
Fractyl Health (NASDAQ: GUTS), una empresa de terapias metabólicas, presentará nuevos datos preclínicos de su plataforma de terapia génica pancreática Rejuva Smart GLP-1 en la 85ª Sesión Científica de la American Diabetes Association. La presentación, programada para el 22 de junio de 2025, mostrará los resultados de un estudio titulado "Terapia génica pancreática basada en GLP-1 de dosis única previene la obesidad y la diabetes en ratones alimentados con dieta alta en grasas." La sesión de pósters se llevará a cabo en la conferencia ADA en Chicago del 20 al 23 de junio de 2025, con la presentación específica programada de 12:30 a 13:30 en el Salón F1. Los datos estarán disponibles en el sitio web de Fractyl después de la presentación en la conferencia.
대사 치료제 회사인 Fractyl Health(NASDAQ: GUTS)는 미국 당뇨병 협회(ADA)의 제85회 학술 세션에서 Rejuva Smart GLP-1 췌장 유전자 치료 플랫폼의 새로운 전임상 데이터를 발표할 예정입니다. 2025년 6월 22일에 예정된 발표에서는 '단일 투여 GLP-1 기반 췌장 유전자 치료가 고지방 식이 쥐에서 비만과 당뇨병을 예방한다'는 제목의 연구 결과를 선보입니다. 포스터 세션은 2025년 6월 20일부터 23일까지 시카고에서 열리는 ADA 학회에서 진행되며, 구체적인 발표는 F1홀에서 12:30부터 13:30까지 예정되어 있습니다. 발표 후 데이터는 Fractyl 웹사이트에서 확인할 수 있습니다.
Fractyl Health (NASDAQ : GUTS), une entreprise spécialisée dans les thérapies métaboliques, présentera de nouvelles données précliniques issues de sa plateforme de thérapie génique pancréatique Rejuva Smart GLP-1 lors des 85èmes Sessions Scientifiques de l'American Diabetes Association. La présentation, prévue pour le 22 juin 2025, dévoilera les résultats d'une étude intitulée « Thérapie génique pancréatique à dose unique basée sur le GLP-1 prévient l'obésité et le diabète chez des souris nourries avec un régime riche en graisses ». La session poster se tiendra lors de la conférence ADA à Chicago du 20 au 23 juin 2025, avec une présentation spécifique programmée de 12h30 à 13h30 dans la salle F1. Les données seront disponibles sur le site web de Fractyl après la présentation à la conférence.
Fractyl Health (NASDAQ: GUTS), ein Unternehmen für metabolische Therapien, wird neue präklinische Daten seiner Rejuva Smart GLP-1 Pankreas-Gen-Therapieplattform auf der 85. Wissenschaftlichen Sitzung der American Diabetes Association präsentieren. Die Präsentation ist für den 22. Juni 2025 geplant und zeigt Ergebnisse einer Studie mit dem Titel „Einmalige GLP-1-basierte Pankreas-Gen-Therapie verhindert Fettleibigkeit und Diabetes bei mit fettreicher Nahrung gefütterten Mäusen“. Die Postersession findet auf der ADA-Konferenz in Chicago vom 20. bis 23. Juni 2025 statt, die spezifische Präsentation ist von 12:30 bis 13:30 Uhr in Halle F1 angesetzt. Die Daten werden nach der Konferenzpräsentation auf der Website von Fractyl verfügbar sein.
Positive
None.
Negative
None.
BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association’s (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.
Poster Presentation Details
Session Title: Late Breaking Poster Session Abstract Title: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice Poster Number: 1970-LB Date and Time: Sunday, June 22, 2025, 12:30 p.m. – 1:30 p.m. Location: Poster Hall (Hall F1, Level 3)
The poster will be available via the Presentations & Publications section of the Fractyl website following the poster session at the conference.
About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.
About Rejuva® Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
Contacts
Media Contact Jessica Cotrone, Head of Corporate Communications jcotrone@fractyl.com, 978.760.5622
Investor Contact Brian Luque, Head of Investor Relations and Corporate Development IR@fractyl.com, 951.206.1200
FAQ
What will Fractyl Health (GUTS) present at the ADA Scientific Sessions 2025?
Fractyl Health will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform, specifically showing results from a study on preventing obesity and diabetes in high-fat-fed mice.
When and where is Fractyl Health's (GUTS) presentation at the ADA Scientific Sessions 2025?
The presentation is scheduled for Sunday, June 22, 2025, from 12:30-1:30 PM in the Poster Hall (Hall F1, Level 3) in Chicago, Illinois.
What is the focus of Fractyl Health's (GUTS) gene therapy research?
Fractyl Health's research focuses on their Rejuva Smart GLP-1 pancreatic gene therapy platform, aimed at treating the root causes of obesity and type 2 diabetes.
Where can investors find Fractyl Health's (GUTS) ADA presentation materials?
The poster presentation will be available in the Presentations & Publications section of Fractyl's website following the conference session.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
